Fisher & Paykel Healthcare initiated with an Equal Weight at Morgan Stanley Morgan Stanley analyst David Bailey initiated coverage of Fisher & Paykel Healthcare with an Equal Weight rating and NZ$36.30 price target. A strong EPS outlook over the next three years is underpinned by new applications growth in the Hospital segment and recent obstructive sleep apnea mask launches, but the introduction of U.S. tariffs presents potential delays to margin targets, the analyst tells investors.
Market Data 
Markets 
AI
